Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur...
Voir le projet

 43

 TERMINÉ 

Common mechanisms and pathways in Stroke and Alzheimer's disease. (CoSTREAM)

Date du début: 1 déc. 2015, Date de fin: 30 nov. 2020,

Common mechanisms and pathways in Stroke and Alzheimer's disease.It has long been recognized that stroke and (Alzheimer’s Disease) AD often co-occur and have an overlapping pathogenesis. As such, these two diseases are not considered fellow travelers, but rather partners in crime. This multidisciplinary consortium includes epidemiologists, geneticists, radiologists, neurologists with a longstandin...
Voir le projet

 11

 TERMINÉ 
The ability of cells to polarize underlies the most basic biological functions such as motility and response to external challenges, but also the formation and maintenance of tissues in a multicellular organism. The importance of cell polarity is underscored by the fact that cell polarity is essential for animal development and is perturbed in disease states such as cancer. Understanding cell pola...
Voir le projet

 9

 TERMINÉ 

Platform foR European Preparedness Against (Re-)emerging Epidemics (PREPARE)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

Far from receding, the threats posed by infections with epidemic potential grow ever greater. Although Europe has amongst the best healthcare systems in the world, and also the world’s supreme researchers in this field, we lack co-ordination and linkage between networks that is required to respond fast to new threats. This consortium of consortia will streamline our response, using primary and sec...
Voir le projet

 27

 TERMINÉ 
The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express...
Voir le projet

 49

 TERMINÉ 

Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Voir le projet

 30

 TERMINÉ 

Human Brain Project Specific Grant Agreement 1 (HBP SGA1)

Date du début: 1 avr. 2016, Date de fin: 31 mars 2018,

Understanding the human brain is one of the greatest scientific challenges of our time. Such an understanding can provide profound insights into our humanity, leading to fundamentally new computing technologies, and transforming the diagnosis and treatment of brain disorders. Modern ICT brings this prospect within reach. The HBP Flagship Initiative (HBP) thus proposes a unique strategy that uses I...
Voir le projet

 126

 TERMINÉ 

European Consortium for Communicating Stem Cell Research (EuroStemCell)

Date du début: 1 janv. 2015, Date de fin: 31 mars 2018,

The European Consortium for Communicating Stem Cell Research (EuroStemCell) unites 33 partner institutions, that collectively represent >400 stem cell research groupings across Europe. Our common goal is to provide trusted high quality information on stem cells accessible to citizens and stakeholders across Europe, through support and further development of the multi-lingual European Stem Cell Inf...
Voir le projet

 32

 TERMINÉ 

Pathogen COinfection: HIV, Tuberculosis, Malaria and Hepatitis C virus (PathCO)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

Acquired immune deficiency (AIDS), tuberculosis (TB) and malaria are the primary infectious diseases causing death world wide. In addition to these pathogens, 170 million people are infected with hepatitis C virus (HCV), which leads to chronic liver disease. Because of shared routes of transmission, HCV co-infection is recognized as a major cause of morbidity and mortality among HIV-1 infected per...
Voir le projet

 11

 TERMINÉ 
Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical sy...
Voir le projet

 23

 TERMINÉ 

Advanced Immunization Technologies (ADITEC)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and...
Voir le projet

 53

 TERMINÉ 

United in Diversity - Wir Sind Europäer

Date du début: 1 sept. 2015, Date de fin: 31 août 2017,

In a problematic international context, in which more and more people are afraid of, or even show rejection towards persons with different backgrounds, cultures, or abilities, our « United in Diversity – Wir Sind Europäer » project aims at helping European students from five highschools all over Europe to discover themselves, to discover other ways of life and cultures, and to show more respect to...
Voir le projet

 5

 TERMINÉ 
To contribute to the development of vaccines against Shigella and ETEC for children of the developing world, STOPENTERICS will provide novel solutions by imposing a two-fold paradigm switch: (i) to break the dogma of serotype-specificity by inducing a cross-protective immunity (ii) to improve the immunogenicity of Shigella glycoconjugates by using synthetic oligosacharides mimicking the lipopolysa...
Voir le projet

 20

 TERMINÉ 

Quantitative T cell Immunology (QuanTI)

Date du début: 1 mai 2013, Date de fin: 30 avr. 2017,

The primary objective of this ITN is to train a new generation of European quantitative immunologists, who will be able to address challenges arising in Systems Immunology. This will be achieved with the proposed Network, Quantitative T cell Immunology (QuanTI), that will train 11 ESRs and 4 ERs, bringing together renowned experimental and theoretical scientists from private and academic instituti...
Voir le projet

 12

 TERMINÉ 
Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories wh...
Voir le projet

 29

 TERMINÉ 

A common European approach to the regulatory testing of nanomaterials (NANOREG)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,

The innovative and economic potential of Manufactured Nano Materials (MNMs) is threatened by a limited understanding of the related EHS issues. While toxicity data is continuously becoming available, the relevance to regulators is often unclear or unproven. The shrinking time to market of new MNM drives the need for urgent action by regulators. NANoREG is the first FP7 project to deliver the answe...
Voir le projet

 73

 TERMINÉ 

Biomarkers For Enhanced Vaccine Safety (BIOVACSAFE)

Date du début: 1 mars 2012, Date de fin: 31 déc. 2016,

BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveil...
Voir le projet

 24

 TERMINÉ 

Dengue research Framework for Resisting Epidemics in Europe (DENFREE)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,

"WHO estimates that one of the main consequences of global warming will be an increased burden of vector-borne diseases. Among these, dengue appears to be particularly problematic, with tens of millions of cases of dengue fever estimated to occur annually, including up to 500,000 cases of the life-threatening dengue hemorrhagic fever/dengue shock syndrome. In recent years, the global burden of den...
Voir le projet

 15

 TERMINÉ 
"The increasing number of bacteria resistant to all antibiotics and antimicrobials and the virtual lack of antiviral drugs make necessary to develop therapeutics based on new targets/approaches. European-wide-acting sectors must permanently improve their capabilities and capacities to cope with these challenges. Thus, the demand for experts trained to understand infectious diseases in their whole ...
Voir le projet

 11

 TERMINÉ 
The capacity of zoonotic RNA viruses to emerge as major agents of human disease can appear limitless. Current intervention strategies have demonstrated limited success. Rapid, innovative and effective solutions are needed to reduce the apparently accelerating process of zoonotic disease emergence. We will study the following zoonotic viruses with epidemic potential in Europe: influenza virus, hepa...
Voir le projet

 20

 TERMINÉ 
"In the research part we will deal with the basic principles of the innate immune defense used to control tumors and viral infections with a focus on NK and NK/T cells, including analysis of NK receptor genomics/epigenetics, gene polymorphisms/disease linkage, differentiation of hitherto unrecognized NK cell subpopulations and novel ligands for NK receptors exposed by tumor and/or virally infected...
Voir le projet

 12

 TERMINÉ 

The Human Brain Project (HBP)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2016,

Understanding the human brain is one of the greatest challenges facing 21st century science. If we can rise to the challenge, we can gain profound insights into what makes us human, develop new treatments for brain diseases and build revolutionary new computing technologies. Today, for the first time, modern ICT has brought these goals within sight. The goal of the Human Brain Project, part of the...
Voir le projet

 116

 TERMINÉ 
"Cancer is a complex disease involving multiple genetic and epigenetic events occurring, and influencing each other, over a long period of time. Understanding cancer, and ultimately developing effective targeted therapies, will therefore require that mutations and epigenetic alterations be systematically investigated during the multiple stages of disease development, from identifiable pre-neoplast...
Voir le projet

 18

 TERMINÉ 

Innovative anti-influenza drugs excluding viral escape (ANTIFLU)

Date du début: 1 juin 2011, Date de fin: 31 mai 2016,

ANTIFLU is to develop innovative drugs against influenza virus infections based on a novelconcept that precludes the development of viral resistance and ensures efficacy againstupcoming pandemic influenza strains. Viral replication is known to depend on multiple hostfactors. Whilst traditional anti-influenza treatments usually target viral factors, ANTIFLU willaim at drugs interfering with host-re...
Voir le projet

 11

 TERMINÉ 

Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE)

Date du début: 1 oct. 2011, Date de fin: 31 mars 2016,

Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role in the drive towards personalised medicine remains uncertain.Based on harmonised and standardised European population cohorts we have built significant research collabo...
Voir le projet

 31

 TERMINÉ 
This is a proposal from 55 partners from 36 institutes to form a NoE that will seek to integrate European malaria research that is directed towards a better understanding of the basic biology of the parasite, its vector and of the biology of the interactions between the parasite and both its mammalian host and vectors. All the member institutes and researchers have demonstrated both their excellen...
Voir le projet

 40

 TERMINÉ 

Pathogenesis and transmission of influenza virus in pigs (FLUPIG)

Date du début: 1 juil. 2010, Date de fin: 31 déc. 2014,

"FLUPIG aims at a better understanding of the role of pigs in influenza pandemics. Pandemic influenza viruses come from wild birds, but they must adapt to efficient replication and transmission in humans to cause a pandemic. Pigs are considered important intermediate hosts in which avian viruses adapt to mammals before they transmit to humans. However, the exact role of pigs is unclear, as is the ...
Voir le projet

 10

 TERMINÉ 
54 partners from 34 institutes have formed an EC-funded Network of Excellence (NoE) in basic malaria research, the European Virtual Institute for Malaria Research (EVIMalaR). Over the previous >5 years as the NoE Biomalpar these partners successfully broke down many barriers to cooperation pursuing a programme of integrated research. This was greatly assisted by the Biomalpar PhD School whose stud...
Voir le projet

 14

 TERMINÉ 
The overall objective of EIMID-ITN is to train ten early stage researchers to join the next generation of world experts in the biology of infectious diseases and specifically in the mechanisms of host-pathogen interaction. The project will be carried out within the highly successful European collaboration EIMID (European Initiative for Basic Research in Microbiology and Infectious Diseases) that b...
Voir le projet

 6

 TERMINÉ 
"The EMPERIE (European Management Platform for Emerging and Re-emerging Infectious disease Entities) consortium has its roots in the lessons learned by the majority of the participating centres during the recent SARS and HPAI H5N1 outbreaks. The mission of EMPERIE is “to contribute to effectively countering the potential public health threat caused by new and emerging infectious diseases in Europe...
Voir le projet

 12

 TERMINÉ 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Date du début: 1 mai 2009, Date de fin: 30 avr. 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises,...
Voir le projet

 52

 TERMINÉ 

Host and viral factors in acute hepatitis C (HEPACUTE)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2014,

Chronic hepatitis C is one of the most common chronic viral infections of humans and a major cause of chronic liver disease, cirrhosis and liver cancer. Still about 4 million new infections occur world-wide each year with 50-85% of patients progressing to chronic hepatitis C. Currently there is no marker to predict spontaneous viral clearance and to guide treatment decisions.The major objectives o...
Voir le projet

 17

 TERMINÉ 

EUROpean consortium on NEUTralising antibodies using gp41 (EURONEUT-41)

Date du début: 1 janv. 2008, Date de fin: 31 mars 2014,

There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed ...
Voir le projet

 19

 TERMINÉ 

Research capacity for the implementation of genetic control of mosquitoes (INFRAVEC)

Date du début: 1 sept. 2009, Date de fin: 28 févr. 2014,

Mosquitoes transmit a variety of infectious diseases that cause a tremendous burden to public health. Due to climate changes and to the increase in international trade and tourism the threats posed by mosquitoes are increasingly affecting large parts of Europe, causing understandable concerns among the populations of many Member States. Control methods, mainly based on insecticide usage, are strug...
Voir le projet

 31

 TERMINÉ 
This proposal aims to develop and implement efficacy of clinical trials with adult, tissue stem cells for degenerative diseases of epithelia and skeletal muscle. Extraordinary progress in the understanding of several key features of stem cells has been rapidly translated into novel cell therapy protocols that have yielded positive results in pre-clinical models of genetic and acquired diseases and...
Voir le projet

 20

 TERMINÉ 
Brain disorders, in particular neurodegenerative diseases and mental illnesses are among the most prevalent and debilitating diseases. Because they are chronic, quality of life and socio-economic prospects are dramatically impaired. Increased life expectancy further enhances the impact of brain dysfunction on society. In coming decades this burden will grow into one of most pressing and costly pro...
Voir le projet

 14

 TERMINÉ 

Predicting antibiotic resistance (PAR)

Date du début: 1 avr. 2010, Date de fin: 31 mars 2013,

"The aim of this proposal is to describe and predict the dynamics of antibiotic resistance development at the level of the drug target, the microbe and the host. That is, we want to generate the knowledge required to be able to connect resistance mechanism --> bacterial physiology and fitness --> bacterial survival within a host --> bacterial spread between hosts. To achieve this goal we will deve...
Voir le projet

 12

 TERMINÉ 
"The EIMID-IAPP training programme is part of the European Initiative for Basic Research in Microbiology and Infectious Diseases (EIMID), created in 2003 by scientists of five European centres of excellence (the Max Planck Institute for Infection Biology in Berlin, the CMMI at Imperial College in London, the Institut Pasteur in Paris, the Karolinska Institutet in Stockholm; and the vaccine company...
Voir le projet

 7

 TERMINÉ 

Development of cardiomyocyte replacement strategy for the clinic (CARDIOCELL)

Date du début: 1 mai 2009, Date de fin: 31 oct. 2012,

"Heart failure as a result of myocardial infarction or ischemic heart disease is a major health problem in Europe. Currently the only long term solution is heart transplantation but one in three patients die while awaiting a match. Transplantation of an alternative cell source is extremely attractive but has so far met with very little success. Thus, skeletal muscle myoblasts led to recurrent arrh...
Voir le projet

 7

 TERMINÉ 

European Consortium for Systematic Stem Cell Biology (EUROSYSTEM)

Date du début: 1 mars 2008, Date de fin: 31 août 2012,

EuroSyStem brings together elite European research teams to create a unique and world-leading programme in fundamental stem cell biology. By interconnecting complementary biological and computational expertise we will drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. We will pave the way for application of systems methodology by measuring and modelling...
Voir le projet

 25